anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Diaphragmatic sleep disordered breathing (dSDB) has been recently identified as sleep dysfunction secondary to diaphragmatic weakness in Duchenne muscular dystrophy (DMD). However, scoring criteria for the identification of dSDB are missing.This study aimed to define and validate dSDB scoring criteria and to evaluate whether dSDB severity correlates with respiratory progression in DMD.
METHODS: Scoring criteria for diaphragmatic apnoea (dA) and hypopnoeas (dH) have been defined by the authors considering the pattern observed on cardiorespiratory polygraphy (CR) and the dSDB pathophysiology.10 sleep professionals (physiologists, consultants) blinded to each other were involved in a two-round Delphi survey to rate each item of the proposed dSDB criteria (Likert scale 1-5) and to recognise dSDB among other SDB. The scorers' accuracy was tested against the authors' panel.Finally, CR previously conducted in DMD in clinical setting were rescored and diaphragmatic Apnoea-Hypopnoea Index (dAHI) was derived. Pulmonary function (forced vital capacity per cent of predicted, FVC%pred), overnight oxygen saturation (SpO2) and transcutaneous carbon dioxide (tcCO2) were correlated with dAHI.
RESULTS: After the second round of Delphi, raters deemed each item of dA and dH criteria as relevant as 4 or 5. The agreement with the panel in recognising dSDB was 81%, kappa 0.71, sensitivity 77% and specificity 85%.32 CRs from DMD patients were reviewed. dSDB was previously scored as obstructive. The dAHI negatively correlated with FVC%pred (r=-0.4; p<0.05). The total number of dA correlated with mean overnight tcCO2 (r 0.4; p<0.05).
CONCLUSIONS: dSDB is a newly defined sleep disorder that correlates with DMD progression. A prospective study to evaluate dSDB as a respiratory measure for DMD in clinical and research settings is planned.
Frontal-crash sled tests were conducted to assess submarining protection and abdominal injury risk for midsized male occupants in the rear seat of modern vehicles. Twelve sled tests were conducted in four rear-seat vehicle-bucks with twelve post-mortem human surrogates (PMHS). Select kinematic responses and submarining incidence were compared to previously observed performance of the Hybrid III 50th-percentile male and THOR-50M ATDs (Anthropomorphic Test Devices) in matched sled tests conducted as part of a previous study. Abdominal pressure was measured in the PMHS near each ASIS (Anterior Superior Iliac Spine), in the inferior vena cava, and in the abdominal aorta. Damage to the abdomen, pelvis, and lumbar spine of the PMHS was also identified. In total, five PMHS underwent submarining. Four PMHS, none of which submarined, sustained pelvis fractures and represented the heaviest of the PMHS tested. Submarining of the PMHS occurred in two out of four vehicles. In the matched tests, the Hybrid III never underwent submarining while the THOR-50M submarined in three out of four vehicles. Submarining occurred in vehicles having both conventional and advanced (pretensioner and load limiter) restraints. The dominant factors associated with submarining were related to seat pan geometry. While the THOR-50M was not always an accurate tool for predicting submarining in the PMHS, the Hybrid III could not predict submarining at all. The results of this study identify substantive gaps in frontal-crash occupant protection in the rear seat for midsized males and elucidates the need for additional research for rear-seat occupant protection for all occupants.
A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
Nitric oxide (NO) plays an important role as a signalling molecule in the biological system. Organoselenium-coated or grafted biomaterials have the potential to achieve controlled NO release as they can catalyse decomposition of endogenous S-nitrosothiols to NO. However, such biomaterials are often challenged by the loss of the catalytic sites, which can affect the stability in tissue repair applications. In this work, we prepare a diselenide-containing poly(ester urethane)urea (SePEUU) polymer with Se-Se in the backbone, which is further electrospun into fibrous membranes by blending with poly(ester urethane)urea (PEUU) without diselenide bonds. The presence of catalytic sites in the main chain demonstrates stable and long-lasting NO catalytic activity, while the porous structure of the fibrous membranes ensures uniform distribution of the catalytic sites and better contact with the donor-containing solution. PEUU/SePEUU50 in 50/50 mass ratio has a physiologically adapted rate of NO release, with a sustained generation of NO after exposure to PBS at 37 °C for 30 d. PEUU/SePEUU50 has a low hemolysis and protein adsorption, with mechanical properties in the wet state matching those of natural vascular tissues. It can promote the adhesion and proliferation of human umbilical vein endothelial cells in vitro and control the proliferation of vascular smooth muscle cells in the presence of NO generation. This study exhibits the electrospun fibrous membranes have potential for utilizing as hemocompatible biomaterials for regeneration of blood-contacting tissues.
Sepsis is a systemic inflammatory response syndrome caused by the invasion of pathogenic microorganisms. Despite major advances in diagnosis and technology, morbidity and mortality remain high. The level of neutrophil extracellular traps (NETs) is closely associated with the progression and prognosis of sepsis, suggesting the regulation of NET formation as a new strategy in sepsis treatment. Owing to its pleiotropic effects, atorvastatin, a clinical lipid-lowering drug, affects various aspects of sepsis-related inflammation and immune responses. To align closely with clinical practice, we combined it with imipenem for the treatment of sepsis. In this study, we used a cecum ligation and puncture-induced lung injury mouse model and employed techniques including western blot, immunofluorescence, and enzyme-linked immunosorbent assay to measure the levels of NETs and other sepsis-related lung injury indicators. Our findings indicate that atorvastatin effectively inhibited the formation of NETs. When combined with imipenem, it significantly alleviated lung injury, reduced systemic inflammation, and improved the 7-day survival rate of septic mice. Additionally, we explored the inhibitory mechanism of atorvastatin on NET formation in vitro, revealing its potential action through the ERK/NOX2 pathway. Therefore, atorvastatin is a potential immunomodulatory agent that may offer new treatment strategies for patients with sepsis in clinical settings.
BACKGROUND: Hepatitis B, a liver infection caused by the hepatitis B virus (HBV), can develop into a chronic infection that puts patients at high risk of death from cirrhosis and liver cancer. In this study, we aimed to investigate the difference of reactome pre-Notch expression and processing between males and females by using gene to function analysis in FUMA.
METHODS: We analyzed Taiwan Biobank (TWB) data pertaining to 48,874 women and 23,178 men individuals which were collected from 2008 to 2019. According to hepatitis B surface antigen (HBsAg) status in hematology, positive and negative were classified into case and control in the genome-wide association study (GWAS) analysis.
RESULTS: We found 4715 women and 2656 men HBV cases. The genomic risk loci were different between males and females. In male, three risk loci (rs3732421, rs1884575 and Affx-28516147) were detected while eight risk loci (Affx-4564106, rs932745, rs7574865, rs34050244, rs77041685, rs107822, rs2296651 and rs12599402) were found in female. In addition, sex also presented different results. In females, the most significant SNPs are gathered in chromosome 6. However, except for chromosome 6, significant HBV infection SNPs also could be found in chromosome 3 among males. We further investigated gene function in FUMA to identify the difference in reactome pre-Notch expression and processing between males and females. We found that POGLUT1 and HIST1H2BC only appeared in men but not in women.
CONCLUSION: According to our study, the reactome pre-Notch expression including POGLUT1 and HIST1H2BC was associated with a risk of Hepatitis B in Taiwanese men when compared to women.
PURPOSE: A composition for immune activation or prevention and treatment of cancer, containing a yeast mutant Saccharomyces cerevisiae IS2-derived soluble glucan oligomer as an effective ingredient is provided. The glucan oligomer increases the number of immune cells, remarkably improves NO-producing capacity and macrophage phagocytosis and inhibits in vitro proliferation of various cancer cells. Therefore, the composition can be used as the remedy and health food for immunocompromising disease and cancer disease. CONSTITUTION: The pharmaceutical composition contains a soluble glucan oligomer derived from Saccharomyces cerevisiae IS2 as a yeast mutant. The soluble glucan oligomer is prepared by the steps of: culturing Saccharomyces cerevisiae IS2 (KCTC 09559BP) in a liquid medium; inoculating the culture broth of Saccharomyces cerevisiae IS2 (KCTC 09559BP) in a liquid medium, followed by cultivation and centrifugation to separate yeast; adding sodium hydroxide and extracting β-glucan from IS2 cell walls; preparing a soluble glucan oligomer by reaction of the extracted β-glucan and β-glucanase and filtration; and freeze-drying the soluble glucan oligomer. The soluble glucan oligomer has a molecular weight of 50,000 or less. A health food contains the soluble glucan oligomer and food additives.
After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
The study team will approach the schools where the proposed study will take place and will obtain the needed permission to conduct the study in the school premises. Information about the study to all the potential participants will be disseminated through the school management. All the potential participants can approach the study team to learn more about the study and participate in the study. Potential participants approaching the study team will be explained in detail about the project and informed consent and /or assent will be obtained. The participants will be selected based on the proposed inclusion and exclusion criteria of the study.

After the recruitment of the participants, iIn-depth, semi-structured, individual interviews lasting approximately an hour will be conducted in either English or Tamil. This will be conducted by trained qualitative researchers. Interviews will be audiotaped and transcribed verbatim. A qualitative descriptive approach will guide all aspects of the qualitative methods we employ to derive a comprehensive description of participants' experiences that is both deep and meaningful. The IDI guide will be developed following an extensive literature search and discussions with experts in the field, for understanding the participants. The interviews will be conducted by two members of the research team. Face-to-face interviews or online interviews will be conducted after ensuring that the participant is comfortable, and all external disturbances will be taken care or minimized
Many animals routinely make energetic trade-offs to adjust to environmental demands and these trade-offs often have significant implications for survival. For example, environmental hypoxia is commonly experienced by many organisms and is an energetically challenging condition because reduced oxygen availability constrains aerobic energy production, which can be lethal. Many hypoxia-tolerant species downregulate metabolic demands when oxygen is limited; however, certain physiological functions are obligatory and must be maintained despite the need to conserve energy in hypoxia. Of particular interest is immunity (including both constitutive and induced immune functions) because mounting an immune response is among the most energetically expensive physiological processes but maintaining immune function is critical for survival in most environments. Intriguingly, physiological responses to hypoxia and pathogens share key molecular regulators such as hypoxia-inducible factor-1α, through which hypoxia can directly activate an immune response. This raises an interesting question: do hypoxia-tolerant species mount an immune response during periods of hypoxia-induced hypometabolism? Unfortunately, surprisingly few studies have examined interactions between immunity and hypometabolism in such species. Therefore, in this review, we consider mechanistic interactions between metabolism and immunity, as well as energetic trade-offs between these two systems, in hypoxia-tolerant animals but also in other models of hypometabolism, including neonates and hibernators. Specifically, we explore the hypothesis that such species have blunted immune responses in hypometabolic conditions and/or use alternative immune pathways when in a hypometabolic state. Evidence to date suggests that hypoxia-tolerant animals do maintain immunity in low oxygen conditions, but that the sensitivity of immune responses may be blunted.
The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
PURPOSE: To obtain a medicinal form which can orally ingest agonists having bad taste and/or agonists unstable in an aqueous solution in a liquid form capable of being individually administered by coating it with a mixture of water- insoluble polymeric film-forming agent and water-soluble film-forming agent in acidic solutions. CONSTITUTION: This medicinal form is prepared by coating agonists (e.g. terpenamino ether derivatives and antivomitting drugs) which have uncomfortable characteristics stimulating sensory organs or are unstable in an aqueous solution with a mixture consisting of water-insoluble polymeric film-forming agents, e.g. a water-insoluble cellulose derivative, shellac, and a film-forming agent soluble in water only at pH5 or less, e.g. a copolymer between a basic substituted methacrylic ester and a neutral methacrylic ester. When the grains obtained are suspended in water at pH5 and temperature 30 deg.C for 30min., the agonist of 5wt.% or less is supplied in water, and when the grains are suspended in an artificial gastric juice at temperature 37 deg.C for 10min., the agonist of more than 80wt.% is isolated in the aqueous solution.
Anticipating Decline and Providing Therapy (ADAPT) is a program designed to support the implementation of a routine post-ICU cognitive impairment screening and support intervention. The program includes a routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge. Patients with a screening assessment that may be consistent with cognitive impairment or dementia will receive additional resources including a specialized care plan developed by the Sticht Center for Healthy Aging and Alzheimer's Prevention. The specialized care plan is adapted from a health system-based dementia care intervention and designed to support post-ICU cognitive concerns. It was adapted with input from geriatrics, intensive care, and outpatient primary care clinicians. Also conducted are semi-structured interviews with 22 older adult ICU survivors and 6 primary care physicians to elicit preferences and the intervention was further adapted based on these results.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Invention is an inactivated emulsion vaccine against foot and mouth disease type A. Vaccine contains an avirulent and purified antigenic material from the strain of foot and mouth disease A virus No. 2269/VNIIZZh/2015 obtained in a suspension continuous cell line from the kidney of a newborn golden hamster (BHK-21/2-17). Antigenic material is a suspension containing mainly 146S immunogenic components of the foot and mouth disease virus. To produce an emulsion vaccine, use an oil adjuvant Montanide ISA-206 or Montanide ISA-70 in effective ratios.EFFECT: vaccine possesses the high immunogeneicity and is able to provide the effective protection against the homologous agent of the infection persistent in Transcaucasus, Central Asia, Middle and Near East.10 cl, 1 dwg, 9 tbl, 7 ex
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (═S) instead of oxo (═O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
The invention discloses a soothing and repairing composition containing various plant extracts, and belongs to the technical field of cosmetic formulas. The soothing and repairing composition is prepared from the following components in parts by weight: 1 to 10 percent of humectant, 3 to 10 percent of soothing and repairing agent, 0.1 to 3 percent of preservative and the balance of deionized water. The soothing and repairing agent comprises hydrolyzed lupin protein, carob seed extract and vegetarian flower extract. The composition has remarkable relieving and repairing effects, can effectively relieve the problems of red swelling, pain, itch, papule desquamation and the like after skin is stimulated, can quickly repair the damaged barrier function of the skin, and improves the capability of the skin to deal with external damage. The recommended level of addition of the soothing repair composition is 2% to 8% depending on the product formulation. The composition has the advantages of natural non-irritation, obvious effect of relieving and repairing, and the like.
<P>PROBLEM TO BE SOLVED: To provide a simple and low-cost method for testing a clinical and/or medical technique system which provides a reliable message related to performance.  <P>SOLUTION: Simulation of a medical examination course in the system is carried out. One process course plan is selected therefor from multiple process course plans depending on an examination issue. Each process course plan includes multiple process units relating to one another, and system components of the system, an input parameter set, an output parameter set and a transfer function are assigned to each process unit. Based on the transfer function for each individual process unit, an output parameter value and/or performance data are obtained from multiple input parameter values for the process unit. The output parameter value of the process unit is used as an input parameter of the successive process unit in the range of the process course plan.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention discloses a Chinese patent medicament and a Chinese decoction for treating hysteromyoma, belonging to the fields of biology and medicine. The Chinese patent medicament and the Chinese decoction are characterized by being prepared from twelve types of traditional Chinese medicines in a Chinese medicinal formula. The invention has the advantages: the Chinese medicinal formula for treating hysteromyoma belongs to an empirical prescription of a famous pedologist in China. As proved, the Chinese decoction has a good healing effect on hysteromyoma. The Chinese medicinal empirical prescription can be prepared into pills, powder, granules, tablets, capsules and the like of the Chinese patent medicament, so that the advantages of the Chinese patent medicament are brought into play. The Chinese patent medicament and the Chinese decoction are readily available, adapt to urgent demands, are convenient to store, and can be carried along. The research of the Chinese decoction and the Chinese patent medicament has great commercial development prospect.
PURPOSE: To evaluate the efficacy and safety of embolization with or without portal vein stenting for bleeding ectopic jejunal varices in the hepatopetal portal collateral due to extrahepatic portal vein occlusion or stenosis after hepatobiliary and pancreatic surgery.
MATERIALS AND METHODS: This study included consecutive patients who underwent embolization for bleeding ectopic jejunal varices in the hepatopetal collateral due to extrahepatic portal vein occlusion or stenosis after hepatobiliary and pancreatic surgery between September 2012 and December 2020. The safety, technical and clinical success rates (no re-bleeding within 1 month) and re-bleeding-free survival after the first therapy and overall survival were assessed.
RESULTS: Fourteen sessions in 11 patients were included. Four patients (7 sessions) underwent variceal embolization only, and the remaining seven patients (7 sessions) underwent portal vein stenting and variceal embolization. Technical success was achieved in all 14 sessions (100%). Clinical success was achieved in 13 of 14 sessions (92.9%). No treatment-related serious complications including liver failure were observed. One-year and 2-year re-bleeding-free survival rate after the first endovascular therapy in all 11 patients was 90.9 and 60.6%, respectively. Two patients who experienced re-bleeding had repeat embolization treatment. There was no significant difference in re-bleeding-free survival after endovascular therapy between the combination with stenting and embolization group and the embolization-only group (p = 0.13).
CONCLUSION: Embolization with or without portal vein stenting of bleeding ectopic jejunal varices in the hepatopetal portal collateral due to extrahepatic portal vein occlusion or stenosis after hepatobiliary and pancreatic surgery can be considered a safe, effective, and repeatable therapy for long-term hemostasis of uncontrollable bleeding.